Septic arthritis following intra-articular corticosteroid injections: a retrospective analysis
- PMID: 41801449
- PMCID: PMC12971831
- DOI: 10.1007/s00402-026-06262-y
Septic arthritis following intra-articular corticosteroid injections: a retrospective analysis
Abstract
Introduction: Septic arthritis is a rare but devastating complication of intra-articular corticosteroid injection (CSI), associated with significant medical morbidity and poor clinical outcomes. Although previous studies have examined risks associated with CSI, few have tracked patients long-term. This study evaluates the incidence, timing, and patient characteristics related to iatrogenic septic arthritis within 6 months of receiving a large joint CSI, offering new insights to inform clinical practice.
Materials and methods: A retrospective, descriptive cohort study was conducted using SlicerDicer, a software stratification system within Epic, to identify patients diagnosed with septic arthritis within six months of receiving an intra-articular CSI of the hip, knee, or shoulder. Data were collected from a single institution over a 10-year period (July 1, 2010 to July 1, 2020). Individual chart review was used to obtain patient demographics, clinical characteristics, and procedural details for identified cases.
Results: Of 15,021 intra-articular corticosteroid injections performed, 14 cases of septic arthritis were identified within 6 months of the procedure, resulting in an incidence rate of 0.093%. Of the affected patients, 21% had underlying inflammatory arthritis, and 21% had underlying comorbidities resulting in immunosuppression. The median time to diagnosis was 3.5 (range 1–16) weeks post-injection, with a bimodal distribution of infections occurring primarily between 1 and 3 and 7–10 weeks post-injection. Staphylococcus aureus (42%) and coagulase-negative Staphylococcus species (36%) were the most commonly isolated organisms.
Conclusions: Large joint intra-articular CSI presents a low risk (< 0.1%) for developing septic arthritis, but can present up to 16 weeks post-injection. The preliminary observation of bimodal timing and delayed presentation of septic arthritis suggests that a standard two-week surveillance window may not be long enough to fully capture all infections, particularly those involving lower-virulence organisms. These findings highlight the need for informed risk stratification and prolonged vigilance well beyond the immediate post-injection period to identify infectious complications after large joint CSI.
Keywords: Corticosteroids; Intra-articular injections; Procedural complications; Septic arthritis.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests.
References
-
- Hawley S, Prats-Uribe A, Matharu GS, Delmestri A, Prieto-Alhambra D, Judge A et al (2025) Effect of intra-articular corticosteroid injections for knee osteoarthritis on the rates of subsequent knee replacement and post-operative outcomes: a national cohort study of England. BMC Med 23:195 - DOI - PMC - PubMed
-
- Benzon HT, Provenzano DA, Nagpal A, Souza D, Eckmann MS, Nelson AM et al (2025) Use and safety of corticosteroid injections in joints and musculoskeletal soft tissue: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, the American Society of Interventional Pain Physicians, and the International Pain and Spine Intervention Society. Reg Anesth Pain Med. 10.1136/rapm-2024-105656 - DOI - PubMed
LinkOut - more resources
Full Text Sources
